San Diego-based Viking Therapeutics marked alone as a significant competitor within the weight loss drug market in February just after revealing promising information from a mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when offered as being a weekly injection As well as in March th